Pharmaceutical Technology lists five of the most popular tweets on infectious diseases in May 2022 based on data from GlobalData’ Pharma Influencer Platform.
The top tweets are based on total engagements (likes and retweets) received on tweets from more than 191 infectious diseases experts tracked by GlobalData’s Pharma Influencer platform during May 2022.
Go deeper with GlobalData
The most popular tweets on infectious diseases in May 2022: Top five
1. Helen Branswell’s tweet on CDC’s concern over UK’s Monkeypox outbreak
Helen Branswell, an infectious diseases and health reporter at the news website Stat News, shared an article on the Centers for Disease Control and Prevention (CDC) having expressed its concerns over the spread of Monkeypox in the UK, suggesting fears of an undetected transmission of the virus and the possibility of it spreading beyond the UK borders. Citing concerns over the virus to be looking very different from what typically is presumed to be Monkeypox, officials confirm that there are seven confirmed cases and one probable case in the UK since early May. This is considered to be a fairly large number as it is an uncommon virus and rare outside West and Centra Africa, the article detailed.
The article further noted that one of the cases had recently travelled to Nigeria, where the virus is at its endemic stage. However, other have contracted the virus in the UK and have not been in any way connected to the traveller. Moreover, the time of the onset of the cases also did not suggest that the traveller was the source of the infection. Transmission of the virus is assumed to occur through virus-laced droplets. However, experts state that the disease can through direct contact with an infected person’s body fluids or legions, and indirectly through contaminated clothing or linens.
Username: Helen Branswell
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
Twitter handle: @HelenBranswell
Likes: 665
Retweets: 370
2. Peter Hotez’s tweet on over 30 million children receiving the first Corbevax dose in India
Peter Hotez, a vaccine scientist and professor and dean at the National School of Tropical Medicine at the Baylor College of Medicine (BCM), shared an article on more than 30 million (three crore) children aged between 12 and 14 years having received the first dose of the Covid-19 vaccine, according to Mansukh Mandaviya, the Union Health Minister. The vaccination drive for children in the said age group commenced on 16 March 2022, with the biotechnology and biopharmaceutical company, Biological E’s intramuscular vaccine Corbevax that was administered to the children in 28 days, the article detailed.
According to the Ministry of Health and Family Welfare, India has been able to vaccinate 190.48 crore people. In addition, about 30,669,820 children aged between 12-14 years have received the first dose of the Covid-19 vaccine, while 10,200,272 have received the second dose, the article noted. Meanwhile, about 58,770,428 children between the age group of 15-18 years have been administered their first doses of the vaccine and 43,308,651 their second doses.
Username: Prof Peter Hotez
Twitter handle: @PeterHotez
Likes: 470
Retweets: 86
3. Laurie Garrett’s tweet on the ban of Ivermectin for Covid-19 in South Africa
Laurie Garrett, a former senior fellow for global health at the Council on Foreign Relations (CFR), a non-partisan, independent think tank, shared an article on the South African Health Products Regulatory Authority (SAHPRA) terminating the programme guiding the import, store, and use of Ivermectin to treat Covid-19. In addition, doctors who have prescribed the drug for Covid-19 are also expected to report the outcomes of the treatment to SAHPRA.
According to SAHPRA, there is no evidence to support Ivermectin’s therapeutic role in Covid. Instead, it has stated that there is no clinical use of the drug in the prevention or treatment of Covid-19, the article detailed. Despite SAHPRA’s discouragement, individual clinicians and pharmacists are allowed to administer the drug for off-label use and for compounding of Ivermectin oral dosage forms respectively. Ivermectin was regarded as a magic bullet for preventing and treating Covid-19 last year, the article noted.
Username: Laurie Garrett
Twitter handle: @Laurie_Garrett
Likes: 207
Retweets: 83
4. Ian M Mackay’s tweet on rising flu cases in Australia
Ian M Mackay, a scientist and an adjunct associate professor at the University of Queensland, shared an article on the five-year exponential rise in laboratory-confirmed influenza cases in Australia. According to the Australian Influenza Surveillance Report – 2022, the incidence of influenza-like illness (ILI) in the community had increased since March 2022. In addition, about 147,155 notifications had been reported to the National Notifiable Diseases Surveillance System (NNDSS) in the year to date in the country. Out of this, 55,101 notifications had a diagnosis date for the fortnight ending 19 June 2022, the article detailed.
Additionally, in the year to date, 54 influenza-related deaths of the 147,155 notifications of laboratory-confirmed influenza were reported to the NNDSS. Since the start of the surveillance in April 2022, about 989 hospital admissions for influenza were reported throughout sentinel hospitals, among which 6.1% were directly admitted to the intensive care unit (ICU), the report highlighted.
Username: ɪᴀɴ ᴍ ᴍᴀᴄᴋᴀʏ
Twitter handle: @MackayIM
Likes: 170
Retweets: 90
5. Laura Waters’ tweet on doxycycline’s effectiveness against STIs
Laura Waters, a physician, shared an article on how one dose of doxycycline could prevent sexually transmitted infections (STIs), such as gonorrhoea, chlamydia, or syphilis after unprotected sex, according to preliminary results from a clinical trial. The results of this trial that were conducted in Seattle and San Francisco proved to be effective among men and transgender women living with HIV or those taking HIV pre-exposure prophylaxis (PrEP), the article detailed. This has urged clinicians and public health officials to look for new ways to prevent STIs , which has been on the rise across the US and the world since the past six years.
Researchers examined the role of doxycycline post-exposure prophylaxis (DoxyPEP), where participants took 200 milligrams of the antibiotic doxycycline within three days of unprotected sex. The trial data from 554 participants revealed that participants who were randomised to take doxycycline had significantly lower STIs compared to those who did not receive doxycycline, the article noted. In addition, the reduction in STIs was found in participants taking HIV PrEP and those living with HIV. As a result, doxycycline was found to be safe, well-tolerated and effective, the article highlighted.
Username: Laura Waters
Twitter handle: @drlaurajwaters
Likes: 57
Retweets: 17
